Tag:

Johnson & Johnson

Latest Headlines

Latest Headlines

J&J, Endo, Teva and Actavis off the hook in Chicago painkiller lawsuit

Four out of 5 drugmakers sued by the city of Chicago escaped the lawsuit, thanks to a Friday court ruling. The case against Purdue Pharma, however, will go on--albeit in a diminished way.

J&J's DePuy Synthes launches first cellulose-derived dural replacement for neurosurgery

Johnson & Johnson's DePuy Synthes CMF, a unit of the business focused on surgical products for the head, neck and thorax, has launched Synthecel, the first marketed dural replacement made of cellulose for use in brain surgery.

J&J recruits a pioneering expert panel to handle compassionate-use pleas

In an industry first, Johnson & Johnson has collaborated with the NYU School of Medicine to create a panel of experts who will evaluate pleas for access to its experimental meds. And it's being chaired by Arthur Caplan, a nationally recognized bioethicist who has long advocated for a better approach in handling compassionate-use requests.

J&J's 2018 Remicade patent smacked down at PTO again

Johnson & Johnson said the U.S. Patent and Trademark Office rejected a 2018 Remicade patent for the second time, putting the blockbuster anti-inflammatory's exclusivity in jeopardy. But the company also said it would appeal, a process that could take years.

Boston Sci partners with Brainlab, as revenue outlook goes flat and legal costs weigh

Boston Scientific is looking determinedly toward the future with a new partnership with deep brain stimulation player Brainlab and positive data for its peripheral artery disease drug-eluting stent. But the past keeps weighing upon it as litigation costs pile up from vaginal mesh lawsuits and the recent settlement with Johnson & Johnson over the long-standing Guidant dispute.

Belgian molecular Dx player Biocartis raises €100M to advance recent launch of Idylla system

Biocartis has raised €100 million ($109 million) in an IPO that's also managed to trade up in recent days. The company could bring in up to €115 million ($126 million) if the bankers exercise their overallotment. That should be the case, since the IPO was highly oversubscribed--the company said it had more than €650 million ($710 million) in investor demand for the IPO.

From the pharma C-suite: Notable, quotable remarks on Asia, emerging markets for Q1

FiercePharmaAsia combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.

Western firms form band of brothers, but welcome others, in Asian medical device association

Major Western device and medical technology firms launched Asia Pacific Medical Technology Association, or APACMed, pledging the association would unite a fragmented effort to work with regulators across a region that is both lucrative and frustrating on issues ranging from import rules to public tender guidelines.

J&J pulls contraceptives in Canada on potency worries

J&J's Janssen unit is recalling one lot of Ortho-Cept contraceptive tablets because of the potential that the potency of the two active ingredients may not meet specifications, Health Canada reports.

J&J recalls contraceptives for subpotency

J&J's Janssen unit is recalling one lot of Ortho-Cept tablets because of the potential that the potency of the two active ingredients may not meet specifications, Health Canada reports.